IP Library › Granted Patent US 12,257,302
Granted Patent B2
US 12,257,302 · App. 18/504,962 · Granted Mar 25, 2025

Universal vaccine platform

Inventors: Hugh Mason (Phoenix, AZ); Andrew Diamos (Tempe, AZ); Mary Pardhe (Phoenix, AZ); Brandon Favre (Los Gatos, CA)
Assignee: Arizona Board of Regents on Behalf of Arizona State University
A61K39/292A61K39/12A61K39/145A61P31/20C12N7/00A61K2039/505A61K2039/5258A61K2039/575A61K2039/6056A61K2039/70C12N2710/20023C12N2710/20034C12N2710/20071C12N2730/10123C12N2730/10134C12N2730/10171C12N2760/16123C12N2760/16134C12N2760/16171C12N2770/24134C12N2770/24171
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,257,302
App. No.
18/504,962
Granted
Mar 25, 2025
Kind
B2
Abstract

The disclosure relates to vaccination compositions, for example, against human papillomavirus, Zika virus, and flu virus. The disclosure also relates to vectors for producing the virus-like particles and immune complex platforms of the vaccination compositions.

Claims (21)

1. A recombinant immune complex comprising: an immunoglobulin heavy chain; an immunoglobulin light chain; an epitope tag, wherein the immunoglobulin heavy chain binds the epitope tag; and a fragment of a virus protein, wherein the fragment of the virus protein is linked to the N-terminus of the immunoglobulin heavy chain, the epitope tag is linked to the C-terminus of the immunoglobulin heavy chain, and the epitope tag is from a different protein than the virus protein.

2. The recombinant immune complex of claim 1 , wherein the epitope tag is an Ebola antigen.

3. The recombinant immune complex of claim 1 , wherein the immunoglobulin heavy chain is the immunoglobulin heavy chain of humanized 6D8 monoclonal antibody and the epitope tag is the 6D8 epitope tag.

4. The recombinant immune complex of claim 1 , further comprising an immunoglobulin light chain.

5. The recombinant immune complex of claim 1 , wherein the virus protein is HPV minor capsid protein L2 (GenBank Accession No. AGH32604.1).

6. The recombinant immune complex of claim 5 , wherein the fragment of the virus protein comprises at least 8 continuous amino acids from the first 200 amino acid residues from the N-terminus of HPV minor capsid protein L2.

7. The recombinant immune complex of claim 5 , wherein the fragment of the virus protein comprises at least one peptide sequence from the HPV minor capsid protein L2 selected from the group consisting of: amino acid residues 17-36, amino acid residues 56-75, amino acid residues 65-85, and amino acid residues 96-115.

8. The recombinant immune complex of claim 1 , wherein the virus protein is M2e.

9. The recombinant immune complex of claim 8 , wherein the fragment of the virus protein comprises the amino acid sequence set forth in SEQ ID NO. 9.

10. The recombinant immune complex of claim 8 , wherein the fragment of the virus protein comprises the amino acid sequence set forth in SEQ ID NO. 10.

11. The recombinant immune complex of claim 1 , wherein the virus protein is selected from the group consisting of: zika virus E protein domain 3 protein (ZE3), zika virus fusion loop antigen (ZE), and zika virus soluble envelope protein (Zse).

12. The recombinant immune complex of claim 11 , wherein the fragment of the virus protein comprises amino acid residues 591-696 or amino acid residues 352-412 of GenBank Accession No. AMC13911.1.

13. The recombinant immune complex of claim 11 , wherein the recombinant immune complex is encoded by the plasmid of SEQ ID NO. 36 or SEQ ID NO. 37.

14. A method of generating an immune response against a virus in a mammalian subject, the method comprising administering to the mammalian subject a recombinant immune complex (RIC), the RIC comprising:

an immunoglobulin heavy chain;

an epitope tag, wherein the immunoglobulin heavy chain binds the epitope tag; and

a fragment of the virus protein,

wherein the fragment of the virus protein is linked to the C-terminus of the immunoglobulin heavy chain, the epitope tag is linked to the C-terminus of the fragment of the virus protein, and the epitope tag is from a different protein than the virus protein.

15. The method of claim 14 , wherein the epitope tag is an Ebola antigen.

16. The method of claim 14 , wherein the immunoglobulin heavy chain is the immunoglobulin heavy chain of humanized 6D8 monoclonal antibody and the epitope tag is the 6D8 epitope tag.

17. The method of claim 14 , wherein the RIC further comprises an immunoglobulin light chain.

Assignments (2)
LICENSE Recorded Aug 25, 2025
From: ARIZONA STATE UNIVERSITY-TEMPE CAMPUS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 072524/0911 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 8, 2024
From: MASON, HUGH; DIAMOS, ANDREW; PARDHE, MARY; FAVRE, BRANDON
To: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
Reel/Frame 068838/0909 →
Continuity (5)
Continuation 17367296 · Jul 2, 2021
Continuation 16404698 · May 6, 2019
Provisional Application 62821599 · Mar 21, 2019
Provisional Application 62667414 · May 4, 2018
Related Publication 20240216502A1 · Jul 4, 2024
References Cited (262)
US 7883843B2 · Milich · 2011 [cited by applicant]
US 8513397B2 · Mason · 2013 [cited by applicant]
US 9506079B2 · Mason · 2016 [cited by applicant]
US 10080799B2 · Mason · 2018 [cited by applicant]
US 10125373B2 · Mason · 2018 [cited by applicant]
US 20140127749A1 · Mason · 2014 [cited by applicant]
US 20190194680A1 · Mason · 2019 [cited by applicant]
US 20200222521A1 · Roland · 2020 [cited by applicant]
US 20200407741A1 · Mason · 2020 [cited by applicant]
US 20210115456A1 · Mason · 2021 [cited by applicant]
WO 2010025285 · 2010 [cited by applicant]
WO 2011100508 · 2011 [cited by applicant]
WO 2012145759 · 2012 [cited by applicant]
WO 2014116721 · 2014 [cited by applicant]
WO 2019010135 · 2019 [cited by applicant]
WO 2019169409 · 2019 [cited by applicant]
WO 2020223516 · 2020 [cited by applicant]
Dreyfus, C. et al., “Highly Conserved Protective Epitopes on Influenza B Viruses”, Science, Sep. 2012, vol. 337, No. 6100, pp. 1343-1348 <DOI:10.1126/science.1222908>. [cited by applicant]
Durbin, A. et al., “An update on Zika vaccine developments”, Expert Review of Vaccines, Jul. 2017 (available online Jun. 2017), vol. 16, No. 8, pp. 781-787 <DOI:10.1080/14760584.2017.1345309>. [cited by applicant]
Ebrahimi, S. et al., “In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza a isolates circulating in Iran”, Virology… [cited by applicant]
Eichelberger, M. et al., “Neuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectiveness”, Current Opinion in Immunology, Aug. 2018 (available online Apr. 2018), v… [cited by applicant]
Eisenberg, R., “The specificity and polyvalency of binding of a monoclonal rheumatoid factor”, Immunochemistry, Apr. 1976 (available online Mar. 2003), vol. 13, No. 4, pp. 355-359 <DOI:10.1016/0019-2791(76)90347-5>. [cited by applicant]
Eisfeld, A. et al., “At the centre: influenza A virus ribonucleoproteins”, Nature Reviews Microbiology, Jan. 2015 (available online Nov. 2014), vol. 13, No. 1, pp. 28-41 <DOI:10.1038/nrmicro3367>. [cited by applicant]
El Bakkouri, K. et al., “Universal Vaccine Based on Ectodomain of Matrix Protein 2 of Influenza A: Fc Receptors and Alveolar Macrophages Mediate Protection”, The Journal of Immunology, Jan. 2011, vol. 186, No. 2, pp. 10… [cited by applicant]
Eliasson, D. et al., “M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection”, Mucosal Immunology, Jan. 2018 (available online Mar. 2017), vol. 11, No. 1, pp. 273-289 <DOI:10.1038/mi… [cited by applicant]
Ellebedy, A. et al., “Induction of broadly cross-reactive antibody responses to the influenza HA stem region rollowing H5N1 vaccination in humans”, Proceedings of the National Academy of Sciences of the United States of… [cited by applicant]
Embers, M. et al., “Protective Immunity to Rabbit Oral and Cutaneous Papillomaviruses by Immunization with Short Peptides of L2, the Minor Capsid Protein”, Journal of Virology, Oct. 2002, vol. 76, No. 19, pp. 9798-9805 … [cited by applicant]
Fan, J. et al., “Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys”, Vaccine, Aug. 2004 (available online Mar. 2004), vol. 22, No. 23-24, pp. 2993-3003 <DOI:10.101… [cited by applicant]
Favre, B., “The Development of a Plant-Expressed M2e-Based Universal Influenza Vaccine”, undergraduate thesis defense, Apr. 2018, 50 slides. [cited by applicant]
Fiers, W. et al., “A “universal” human influenza A vaccine”, Virus Research, Jul. 2004 (available online Apr. 2004), vol. 103, No. 1-2, pp. 173-176 <DOI:10.1016/j.virusres.2004.02.030>. [cited by applicant]
Fiers, W. et al., “M2e-based universal influenza A vaccine”, Vaccine, Oct. 2009, vol. 27, No. 45, pp. 6280-6283 <DOI:10.1016/j.vaccine.2009.07.007>. [cited by applicant]
Fischer, R. et al., “Molecular farming of pharmaceutical proteins”, Transgenic Research, Aug. 2000, vol. 9, No. 4-5, pp. 279-299 <DOI:10.1023/A:1008975123362>. [cited by applicant]
Flannery, B. et al., “Early Estimates of Seasonal Influenza Vaccine Effectiveness—United States, Jan. 2015”, Morbidity and Mortality Weekly Report, Jan. 2015, vol. 64, No. 1, pp. 10-15. [cited by applicant]
Flannery, B. et al., “Interim Estimates of 2013-14 Seasonal Influenza Vaccine Effectiveness—United States, Feb. 2014”, Morbidity and Mortality Weekly Report, Feb. 2014, vol. 63, No. 7, pp. 137-142. [cited by applicant]
Flannery, B. et al., “Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness—United States, Feb. 2017”, Morbidity and Mortality Weekly Report, Feb. 2017, vol. 66, No. 6, pp. 167-171 <DOI:10.15585/mmwr.mm6… [cited by applicant]
Flannery, B. et al., “Interim Estimates of 2017-18 Seasonal Influenza Vaccine Effectiveness—United States, Feb. 2018”, Morbidty and Mortality Weekly Report, Feb. 2018, vol. 67, No. 6, pp. 180-185 <DOI:10.15585/mmwr.mm67… [cited by applicant]
Fridman, W., “Fc receptors and immunoglobulin binding factors”, The FASEB Journal, Sep. 1991, vol. 5, No. 12, pp. 2684-2690 <DOI: 10.1096/fasebj.5.12.1916092>. [cited by applicant]
Fu, T. et al., “Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys”, Vaccine, Feb. 2009 (available online Jan. 2009), vol.… [cited by applicant]
Gallie, D., “The 5'-leader of tobacco mosaic virus promotes translation through enhanced recruitment of Eif4f”, Nucleic Acids Research, Aug. 2002, vol. 30, No. 15, pp. 3401-3411 <DOI:10.1093/nar/gkf457>. [cited by applicant]
Gambhira, R. et al., “A Protective and Broadly Cross-Neutralizing Epitope of Human Papillomavirus L2”, Journal of Virology, Dec. 2007, vol. 81, No. 24, pp. 13927-13931 <DOI:10.1128/JVI.00936-07>. [cited by applicant]
Gambhira, R. et al., “Protection of Rabbits against Challenge with Rabbit Papillomaviruses by Immunization with the N Terminus of Human Papillomavirus Type 16 Minor Capsid Antigen L2”, Journal of Virology, Nov. 2007, vo… [cited by applicant]
Gaukroger, J. et al., “Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus- neutralizing antibodies”, Journal of General Virology, Jan. 1996 (available online Jul. 1996), vol. 77, … [cited by applicant]
Gerhard, W. et al., “Role of the B-cell response in recovery of mice from primary influenza virus infection”, Immunological Reviews, Oct. 1997 (available online Apr. 2006), vol. 159, No. 1, pp. 95-103 <DOI:10.1111/i.160… [cited by applicant]
Grgacic, E. et al., “Virus-like particles: Passport to immune recognition”, Methods, Sep. 2006, vol. 40, No. 1, pp. 60-65 <DOI:10.1016/j.ymeth.2006.07.018>. [cited by applicant]
Guerrero, R. et al., “Recombinant Norwalk Virus-Like Particles Administered Intranasally to Mice Induce Systemic and Mucosal (Fecal and Vaginal) Immune Responses”, Journal of Virology, Oct. 2001, vol. 75, No. 20, pp. 97… [cited by applicant]
Halweg, C. et al., “The Rb7 Matrix Attachment Region Increases the Likelihood and Magnitude of Transgene Expression in Tobacco Cells: A Flow Cytometric Study”, The Plant Cell, Feb. 2005, vol. 17, No. 2, pp. 418-429 <DOI… [cited by applicant]
Hause, B. et al., “Characterization of a Novel Influenza Virus in Cattle and Swine: Proposal for a New Genus in the Orthomyxoviridae Family”, mBio, Mar./Apr. 2014, vol. 5, No. 2, article e00031, 10 pages <DOI:10.1128/mB… [cited by applicant]
Hay, A. et al., “The evolution of human influenza viruses”, Philosophical Transactions of the Royal Society B, Dec. 2001, vol. 356, No. 1416, pp. 1861-1870 <DOI:10.1098/rstb.2001.0999>. [cited by applicant]
Hefferon, K., “DNA Virus Vectors for Vaccine Production in Plants: Spotlight on Geminiviruses”, Vaccines, Aug. 2014, vol. 2, No. 3, pp. 642-653 <DOI:10.3390/vaccines2030642>. [cited by applicant]
Heinz, F. et al., “Field effectiveness of vaccination against tick-borne encephalitis”, Vaccine, Oct. 2007 (available online Aug. 2007), vol. 25, No. 43, pp. 7559-7567 <DOI:10.1016/j.vaccine.2007.08.024>. [cited by applicant]
Herr, R. et al., “Evaluation of Two Homologous Proline-Rich Proteins of Coccidioides posadasii as Candidate Vaccines against Coccidioidomycosis”, Infection and Immunity, Dec. 2007, vol. 75, No. 12, pp. 5777-5787 <DOI:10… [cited by applicant]
Hiatt, A. et al., “Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy”, Proceedings of the National Academy of Sciences of the United States of America, Apr. 2… [cited by applicant]
Hiatt, A. et al., “Plant-Derived Monoclonal Antibodies for Prevention and Treatment of Infectious Disease”, Microbiology Spectrum, Jan. 2014, vol. 2, No. 1, 10 pages <DOI:10.1128/microbiolspec.AID-0004-2012>. [cited by applicant]
Hioe, C. et al., “The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120”, Vaccine, Dec. 2009 (available online Oct. 2009), vol. 28, No. 2, pp. 352-360 <DO… [cited by applicant]
Huang, Z. et al., “A DNA replicon system for rapid high-level production of virus-like particles in plants”, Biotechnology and Bioengineering, Jul. 2009 (available online Feb. 2009), vol. 103, No. 4, pp. 706-714 <DOI:10… [cited by applicant]
Huang, Z. et al., “Conformational analysis of hepatitis B surface antigen fusions in an Agrobacterium-mediated transient expression system”, Plant Biotechnology Journal, May 2004 (available online Mar. 2004), vol. 2, No… [cited by applicant]
Huang, Z. et al., “High-level rapid production of full-size monoclonal antibodies in plants by a single-vector DNA replicon system”, Biotechnology and Bioengineering, May 2010 (available online Dec. 2009), vol. 106, No.… [cited by applicant]
Huang, Z. et al., “Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice”, Vaccine, Mar. 2006 (available online Dec. 2005), vol. 24, No. 14, pp. 2506-2513 <DOI:10.1016/j.v… [cited by applicant]
Huber, V. et al., “Distinct Contributions of Vaccine-Induced Immunoglobulin G1 (IgG1) and IgG2a Antibodies to Protective Immunity against Influenza”, Clinical and Vaccine Immunology, Sep. 2006, vol. 13, No. 9, pp. 981-9… [cited by applicant]
Ina, Y. et al., “Statistical analysis of nucleotide sequences of the hemagglutinin gene of human influenza A viruses”, Proceedings of the National Academy of Sciences of the United States of America, Aug. 1994, vol. 91,… [cited by applicant]
Ingle, N. et al., “Inter-Clade Protection Offered by Mw-Adjuvanted Recombinant HA, NP Proteins, and M2e Peptide Combination Vaccine in Mice Correlates with Cellular Immune Response”, Frontiers in Immunology, Jan. 2017, … [cited by applicant]
Inglis, S. et al., “Polypeptides specified by the influenza virus genome: I. Evidence for eight distinct gene products specified by fowl plague virus”, Virology, Oct. 1976 (available Jun. 2004), vol. 74, No. 2, pp. 489-… [cited by applicant]
Iuliano, A. et al., “Estimates of global seasonal influenza-associated respiratory mortality: a modelling study”, The Lancet, Mar. 2018 (available online Dec. 2017), vol. 391, No. 10127, pp. 1285-1300 <DOI:10.1016/S0140… [cited by applicant]
Jackson, L. et al., “Interim adjusted estimates of seasonal influenza vaccine effectiveness—United States, Feb. 2013”, Morbidity and Mortality Weekly Report, Feb. 2013, vol. 62, No. 7, pp. 119-123. [cited by applicant]
Jackson, M. et al., “Burden of medically attended influenza infection and cases averted by vaccination—United States, 2013/14 through 2015/16 influenza seasons”, Vaccine, Jan. 2018 (available online Dec. 2017), vol. 36,… [cited by applicant]
Jackson, M. et al., “Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season”, The New England Journal of Medicine, Aug. 2017, vol. 377, No. 6, pp. 534-543 <DOI:10.1056/NEJMoa1700153>. [cited by applicant]
Jefferis, R., “Glycosylation as a strategy to improve antibody-based therapeutics”, Nature Reviews Drug Discovery, Mar. 2009, vol. 8, pp. 226-234 <DOI:10.1038/nrd2804>. [cited by applicant]
Jegerlehner, A. et al., “A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses”, Vaccine, Aug. 2002 (available online Jun. 2002), vol. 20, No. 25-26, … [cited by applicant]
Jegerlehner, A. et al., “Influenza A Vaccine Based on the Extracellular Domain of M2: Weak Protection Mediated via Antibody-Dependent NK Cell Activity”, Journal of Immunology, May 2004 (available online Apr. 2004), vol.… [cited by applicant]
Kanda, Y. et al., “Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types”, Glycobiology, Jan. 2… [cited by applicant]
Kawana, K. et al., “Common Neutralization Epitope in Minor Capsid Protein L2 of Human Papillomavirus Types 16 and 6”, Journal of Virology, Jul. 1999, vol. 73, No. 7, pp. 6188-6190. [cited by applicant]
Kim, K-H. et al., “Virus-Like Particles Are a Superior Platform for Presenting M2e Epitopes to Prime Humoral and Cellular Immunity against Influenza Virus”, Vaccines, Sep. 2018, vol. 6, No. 4, article 66, 18 pages <DOI:… [cited by applicant]
Kim, M-Y. et al., “Novel vaccination approach for dengue infection based on recombinant immune complex universal platform”, Vaccine, Apr. 2015 (available Feb. 2015), vol. 33, No. 15, pp. 1830-1838 <DOI:10.1016/j.vaccine… [cited by applicant]
Kim, M-Y. et al., “Plant-expressed Fc-fusion protein tetravalent dengue vaccine with inherent adjuvant properties”, Plant Biotechnology Journal, Jul. 2018 (available online Dec. 2017), vol. 16, No. 7, pp. 1283-1294 <DOI… [cited by applicant]
Kim, M. et al., “Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection”, Antiviral Research, Sep. 2013 (available … [cited by applicant]
Kines, R. et al., “The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding”, Proceedings of the National Academy of Sciences of the United States of America, De… [cited by applicant]
Kirkland, T. et al., “Evaluation of the Proline-Rich Antigen of Coccidioides immitis as a Vaccine Candidate in Mice”, Infection and Immunity, Aug. 1998, vol. 66, No. 8, pp. 3519-3522. [cited by applicant]
Kirnbauer, R. et al., “Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic”, Proceedings of the National Academy of Sciences of the United States of America, Dec. … [cited by applicant]
Kolpe, A. et al., “Passively transferred M2e-specific monoclonal antibody reduces influenza A virus transmission in mice”, Antiviral Research, Oct. 2018 (available online Sep. 2018), vol. 158, pp. 244-254 <DOI:10.1016/j… [cited by applicant]
Kondo, K. et al., “Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes”, Journal of Medical Virology, May 2008 (available online Mar. 2008), vol. 80, No. 5, pp. 841-… [cited by applicant]
Kondo, K. et al., “Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region”, Vi… [cited by applicant]
Kosik, I. et al., “Neuraminidase inhibition contributes to influenza A virus neutralization by anti-hemagglutinin stem antibodies”, Journal of Experimental Medicine, Jan. 2019, vol. 216, No. 2, pp. 304-316 <DOI:10.1084/… [cited by applicant]
Koutsky, L. et al., “A Controlled Trial of a Human Papillomavirus Type 16 Vaccine”, The New England Journal of Medicine, Nov. 2002, vol. 347, No. 21, pp. 1645-1651 <DOI:10.1056/NEJMoa020586>. [cited by applicant]
Krammer, F. et al., “Universal Influenza Virus Vaccines That Target the Conserved Hemagglutinin Stalk and Conserved Sites in the Head Domain”, The Journal of Infectious Diseases, Apr. 2019, vol. 219, No. 1, pp. S62-S67 … [cited by applicant]
Krieger, G. et al., “Binding characteristics of three complement dependent assays for the detection of immune complexes in human serum”, Journal of Clinical & Laboratory Immunology, Nov. 1985, vol. 18, No. 3, pp. 129-13… [cited by applicant]
Krishnavajhala, H. et al., “An influenza A virus vaccine based on an M2e-modified alphavirus”, Archives of Virology, Feb. 2018 (available online Oct. 2017), vol. 163, No. 2, pp. 483-488 <DOI:10.1007/s00705-017-3578-8>. [cited by applicant]
Lamb, R. et al', “Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface”, Cell, Mar. 1985 (available online Apr. 2004), vol. 40, No. 3, pp. 627-633 <DOI:10.1016/0092-8674(85)9… [cited by applicant]
Lamb, R., “The Influenza Virus RNA Segments and Their Encoded Proteins”, Genetics of Influenza Viruses (Springer, Vienna), 1983, pp. 21-69. [cited by applicant]
Lazarowitz, S. et al., “Geminiviruses: Genome structure and gene function”, Critical Reviews in Plant Sciences, 1992 (available online Dec. 2008), vol. 11, No. 4, pp. 327-349 <DOI:10.1080/07352689209382350>. [cited by applicant]
Lee, S-Y. et al., “Nucleoprotein vaccine induces cross-protective cytotoxic T lymphocytes against both lineages of influenza B virus”, Clinical and Experimental Vaccine Research, Jan. 2019, vol. 8, No. 1, pp. 54-63 <DOI… [cited by applicant]
Liu, W. et al., “Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design”, Microbes and Infection, Feb. 2005 (a… [cited by applicant]
Lowy, D. et al., “Prophylactic human papillomavirus vaccines”, The Journal of Clinical Investigation, May 2006, vol. 116, No. 5, pp. 1167-1173 <DOI:10.1172/JCI28607>. [cited by applicant]
Lund, J. et al., “Oligosaccharide-protein interactions in IgG can modulate recognition by Fc gamma receptors”, FASEB Journal, Jan. 1995, vol. 9, No. 1, pp. 115-119 <DOI:10.1096/fasebj9.1.7821750>. [cited by applicant]
MacArthur, M. et al., “Influence of proline residues on protein conformation”, Journal of Molecular Biology, Mar. 1991 (available online Oct. 2004), vol. 218, No. 2, pp. 397-412 <DOI:10.1016/0022-2836(91)90721-H>. [cited by applicant]
Mardanova, E. et al., “High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin”, Bioengineered, 2015 (available online Feb. 2016), vol. 7, No. 1, pp. 28-32 <DOI:10.1… [cited by applicant]
Mardanova, E. et al., “Plant-produced Recombinant Influenza A Vaccines Based on the M2e Peptide”, Current Pharmaceutical Design, 2018, vol. 24, No. 12, pp. 1317-1324 <DOI:10.2174/1381612824666180309125344>. [cited by applicant]
Mardanova, E. et al., “Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors”, BMC Biotechnology, May 2015, vol. 15, article… [cited by applicant]
Mariani, L. et al., “HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future”, Journal of Translational Medicine, Oct. 2010, vol. 8, No. 105, 8 pages <DOI:10.1186/1479-5876-8-… [cited by applicant]
Marillonnet, S. et al., “In planta engineering of viral RNA replicons: Efficient assembly by recombination of DNA modules delivered by Agrobacterium”, Proceedings of the National Academy of Sciences of the United States… [cited by applicant]
Markine-Goriaynoff, D. et al., “Increased Efficacy of the Immunoglobulin G2a Subclass in Antibody-Mediated Protection against Lactate Dehydrogenase-Elevating Virus-Induced Polioencephalomyelitis Revealed with Switch Mut… [cited by applicant]
Marusic, C. et al., “N-glycan engineering of a plant-produced anti-CD20-hIL-2 immunocytokine significantly enhances its effector functions”, Biotechnology and Bioengineering, Mar. 2018 (available online Nov. 2017), vol.… [cited by applicant]
Mason, H., “Recombinant immune complexes as versatile and potent vaccines”, Human Vaccines & Immunotherapeutics, Mar. 2016 (available online Jan. 2016), vol. 12, No. 4, pp. 988-989 <DOI:10.1080/21645515.2015.1116655>. [cited by applicant]
Matic, S. et al., “Efficient production of chimeric Human papillomavirus 16 L1 protein bearing the M2e influenza epitope in Nicotiana benthamiana plants”, BMC Biotechnology, Nov. 2011, vol. 11, article 106 <DOI:10.1186/… [cited by applicant]
Matsuzaki, Y. et al., “Clinical Features of Influenza C Virus Infection in Children”, The Journal of Infectious Diseases, May 2006, vol. 193, No. 9, pp. 1229-1235 <DOI:10.1086/502973>. [cited by applicant]
Maverakis, E. et al., “Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: A critical review”, Journal of Autoimmunity, Feb. 2015 (available online Jan. 2015), vol. 57, pp. 1-13 <DOI:10.1016/j.ia… [cited by applicant]
McGeoch, D. et al., “Influenza virus genome consists of eight distinct RNA species”, Proceedings of the National Academy of Sciences of the United States of America, Sep. 1976, vol. 73, No. 9, pp. 3045-3049 <DOI:10.1073… [cited by applicant]
Mechtchriakova, I. et al., “The use of viral vectors to produce hepatitis B virus core particles in plants”, Journal of Virological Methods, Jan. 2006 (available online Aug. 2005), vol. 131, No. 1, pp. 10-15 <DOI:10.101… [cited by applicant]
Milich, D. et al., “Preferential Recognition of Hepatitis B Nucleocapsid Antigens by Th1 or Th2 Cells Is Epitope and Major Histocompatibility Complex Dependent”, Journal of Virology, May 1995, vol. 69, No. 5, pp. 2776-2… [cited by applicant]
Milich, D. et al., “The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen”, Science, Dec. 1986, vol. 234, No. 4782, pp. 1398-1401 <DOI:10.1126/science.3491425>. [cited by applicant]
Mitnaul, L. et al., “Balanced Hemagglutinin and Neuraminidase Activities Are Critical for Efficient Replication of Influenza A Virus”, Journal of Virology, Jul. 2000, vol. 74, No. 13, pp. 6015-6020 <DOI:10.1128/JVI.74.1… [cited by applicant]
Moñoz, N. et al., “Against which human papillomavirus types shall we vaccinate and screen? the international perspective”, International Journal of Cancer, Aug. 2004 (available online Apr. 2004), vol. 111, No. 2, pp. 27… [cited by applicant]
Moscicki, A-B., “Hpv Vaccines: Today and in the Future”, Journal of Adolescent Health, Oct. 2008 (available online Sep. 2008), vol. 43, No. 4, pp. S26-S40 <DOI:10.1016/j.jadohealth.2008.07.010>. [cited by applicant]
Mosmann, T. et al., “TH1 and TH2 Cells: Different Patterns of Lymphokine Secretion Lead to Different Functional Properties”, Annual Review of Immunology, Apr. 1989, vol. 7, No. 1, pp. 145-173 <DOI:10.1146/annurev.iy.07.… [cited by applicant]
Mosnier, A. et al., “Influenza B burden during seasonal influenza epidemics in France”, Medecine et Maladies Infectieuses, Feb. 2017 (available online Jan. 2017), vol. 47, No. 1, pp. 11-17 <DOI:10.1016/j.medmal.2016.11.… [cited by applicant]
Most, J. et al., “Consecutive Infections With Influenza A and B Virus in Children During the 2014-2015 Seasonal Influenza Epidemic”, The Journal of Infectious Diseases, Oct. 2016 (available online Apr. 2016), vol. 214, … [cited by applicant]
Murray, K. et al., “The Core Antigen of Hepatitis B Virus as a Carrier for Immunogenic Peptides”, Biological Chemistry, Mar. 1999 (available online Jun. 2005), vol. 380, No. 3, pp. 277-283 <DOI:10.1515/BC.1999.038>. [cited by applicant]
Nair, H. et al., “Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis”, The Lancet, Dec. 2011 (available online Nov. 2011), vol. 378, No. 9807, pp. … [cited by applicant]
Nandi, S. et al., “Techno-economic analysis of a transient plant-based platform for monoclonal antibody production”, mAbs, Sep. 2016 (available online Aug. 2016), vol. 8, No. 8, pp. 1456-1466 <DOI:10.1080/19420862.2016.… [cited by applicant]
Nardelli-Haefliger, D. et al., “Specific Antibody Levels at the Cervix During the Menstrual Cycle of Women Vaccinated With Human Papillomavirus 16 Virus-Like Particles”, Journal of the National Cancer Institute, Aug. 20… [cited by applicant]
National Institute of Allergy and Infectious Diseases (NIAID)., “VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents (DNA)” [online], U.S. National Library of Medicine: ClinicalTrials.gov, Apr. 2017 [ret… [cited by applicant]
Neirynck, S. et al., “A universal influenza A vaccine based on the extracellular domain of the M2 protein”, Nature Medicine, Oct. 1999, vol. 5, No. 10, pp. 1157-1163 <DOI:10.1038/13484>. [cited by applicant]
Nemchinov, L. et al., “Transient expression of the ectodomain of matrix protein 2 (M2e) of avian influenza A virus in plants”, Protein Expression and Purification, Dec. 2007 (available online Jun. 2007), vol. 56, No. 2,… [cited by applicant]
Neuberger, M. et al., “Activation of mouse complement by monoclonal mouse antibodies”, European Journal of Immunology, 1981, vol. 11, No. 12, pp. 1012-1016 <DOI:10.1002/eji.1830111212>. [cited by applicant]
Niwa, R. et al., “IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides”, Journal of Immunological Methods, Nov. 2005 (available online Se… [cited by applicant]
Nobusawa, E. et al., “Comparison of the Mutation Rates of Human Influenza A and B Viruses”, Journal of Virology, Apr. 2006, vol. 80, No. 7, pp. 3675-3678 <DOI:10.1128/JVI.80.7.3675-3678.2006>. [cited by applicant]
Office Action (Non-Final Rejection) dated May 8, 2023 for U.S. Appl. No. 17/367,296 (pp. 1-6). [cited by applicant]
Office Action (Notice of Allowance and Fees Due (PTOL-85)) dated Aug. 16, 2023 for U.S. Appl. No. 17/367,296 (pp. 1-5). [cited by applicant]
Oliveira, E. et al., “The flavivirus capsid protein: Structure, function and perspectives towards drug design”, Virus Research, Jan. 2017 (available online Oct. 2016), vol. 227, pp. 115-123 <DOI:10.1016/j.virusres.2016.… [cited by applicant]
Osterholm, M. et al., “Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis”, Lancet Infectious Diseases, Jan. 2012 (available online Oct. 2011), vol. 12, No. 1, pp. 36-44 <DOI:10.1016… [cited by applicant]
Ozawa, S. et al., “Modeling the Economic Burden of Adult Vaccine-Preventable Diseases in the United States”, Health Affairs, Nov. 2016, vol. 35, No. 11, pp. 2124-2132 <DOI:10.1377/hlthaff.2016.0462>. [cited by applicant]
Palmer, K. et al., “Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes”, Vaccine, Jun. 2006 (available online May 2006), vol. 24, No. 26… [cited by applicant]
Paprotka, T. et al., “Form follows function in geminiviral minichromosome architecture”, Virus Research, Jan. 2015 (available online Nov. 2014), vol. 196, pp. 44-55 <DOI:10.1016/j.virusres.2014.11.004>. [cited by applicant]
Pastrana, D. et al., “Cross-neutralization of cutaneous and mucosal Papillomavirus types with anti-sera to the amino terminus of L2”, Virology, Jul. 2005 (available online May 2005), vol. 337, No. 2, pp. 365-372 <DOI:10… [cited by applicant]
Paules, C. et al., “Chasing Seasonal Influenza-The Need for a Universal Influenza Vaccine”, The New England Journal of Medicine, Jan. 2018, vol. 378, No. 1, pp. 7-9 <DOI:10.1056/NEJMp1714916>. [cited by applicant]
Pejoski, D. et al., “A lipopeptide based on the M2 and HA proteins of influenza A viruses induces protective antibody”, Immunology and Cell Biology, Feb. 2010, vol. 88, No. 5, pp. 601-611 <DOI:10.1038/icb.2010.15>. [cited by applicant]
Pena-Cortes, H. et al., “Signals involved in wound-induced proteinase inhibitor II gene expression in tomato and potato plants”, Proceedings of the National Academy of Sciences of the United States of America, May 1995,… [cited by applicant]
Pepponi, I. et al., “Plant-derived recombinant immune complexes as self-adjuvanting TB immunogens for mucosal boosting of BCG”, Plant Biotechnology Journal, Sep. 2014 (available online Mar. 2014), vol. 12, No. 7, pp. 84… [cited by applicant]
Petukhova, N. et al., “Immunogenicity and protective efficacy of candidate universal influenza A nanovaccines produced in plants by Tobacco mosaic virus-based vectors”, Current Pharmaceutical Design, Feb. 2013 (preprint… [cited by applicant]
Peyret, H. et al., “A protocol for the gentle purification of virus-like particles produced in plants”, Journal of Virological Methods, Dec. 2015 (available online Sep. 2015), vol. 225, pp. 59-63 <DOI:10.1016/j.iviromet… [cited by applicant]
Peyret, H. et al., “Tandem Fusion of Hepatitis B Core Antigen Allows Assembly of Virus-Like Particles in Bacteria and Plants with Enhanced Capacity to Accommodate Foreign Proteins”, PLoS One, Apr. 2015, vol. 10, No. 4, … [cited by applicant]
Phoolcharoen, W. et al., “A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge”, Proceedings of the National Academy of Sciences of the United States of America, Dec. 2011, vol. 108, No. 5… [cited by applicant]
Phoolcharoen, W. et al., “Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana”, Plant Biotechnology Journal, Sep. 2011 (available online Feb. 2011), vol. 9, No. 7, pp. 807-816 <DOI:10.1111/j.467-7… [cited by applicant]
Pumpens, P. et al., “HBV Core Particles as a Carrier for B Cell/T Cell Epitopes”, Intervirology, 2001, vol. 44, No. 2-3, pp. 98-114 <DOI:10.1159/000050037>. [cited by applicant]
Pushko, P. et al., “Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens”, Virology, Jan. 2017 (available online D… [cited by applicant]
Putri, W. et al., “Economic burden of seasonal influenza in the United States”, Vaccine, Jun. 2018 (available online May 2018), vol. 36, No. 27, pp. 3960-3966 <DOI:10.1016/j.vaccine.2018.05.057>. [cited by applicant]
Rabaan, A. et al., “Overview of Zika infection, epidemiology, transmission and control measures”, Journal of Infection and Public Health, Mar.-Apr. 2017 (available online Jun. 2016), vol. 10, No. 2, pp. 141-149 <DOI:10.… [cited by applicant]
Radaev, S. et al., “Recognition of immunoglobulins by Fcγ receptors”, Molecular Immunology, May 2002 (available online Mar. 2002), vol. 38, No. 14, pp. 1073-1083 <DOI:10.1016/S0161-5890(02)00036-6>. [cited by applicant]
Ramirez, A. et al., “A virus-like particle vaccine candidate for influenza A virus based on multiple conserved antigens presented on hepatitis B tandem core particles”, Vaccine, Feb. 2018 (available online Jan. 2018), v… [cited by applicant]
Reed, C. et al., “Estimating Influenza Disease Burden from Population-Based Surveillance Data in the United States”, Plos One, Mar. 2015, vol. 10, No. 3, article e0118369 <10.1371/journal.pone.0118369>. [cited by applicant]
Regnault, A. et al., “FCV Receptor-mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I-restricted Antigen Presentation after Immune Complex Internalization”, Journal of Experimen… [cited by applicant]
Roden, R. et al., “Minor Capsid Protein of Human Genital Papillomaviruses Contains Subdominant, Cross-Neutralizing Epitopes”, Virology, May 2000 (available online May 2002), vol. 270, No. 2, pp. 254-257 <DOI:10.1006/vir… [cited by applicant]
Rohovie, M. et al., “Virus-like particles: Next-generation nanoparticles for targeted therapeutic delivery”, Bioengineering & Translational Medicine, Mar. 2017 (available online Dec. 2016), vol. 2, No. 1, pp. 43-57 <DOI… [cited by applicant]
Rolfes, M. et al., “Annual estimates of the burden of seasonal influenza in the United States: A tool for strengthening influenza surveillance and preparedness”, Influenza and other respiratory viruses, Feb. 2018 (avail… [cited by applicant]
Rosenthal et al., “An intronless form of the tobacco extensin gene terminator strongly enhances transient gene expression in plant leaves”, Plant Mol Biol, (Feb. 10, 2018), vol. 96, pp. 429-443. [cited by applicant]
Rybicki, E., “Plant-made vaccines for humans and animals”, Plant Biotechnology Journal, Jun. 2010 (available online May 2010), vol. 8, No. 5, pp. 620-637 <DOI:10.1111/j.1467-7652.2010.00507.x>. [cited by applicant]
Santi, L. et al., “An efficient plant viral expression system generating orally immunogenic Norwalk virus-like particles”, Vaccine, Mar. 2008 (available online Feb. 2008), vol. 26, No. 15, pp. 1846-1854 <DOI:10.1016/j.v… [cited by applicant]
Schellenbacher, C. et al., “Developments in L2-based human papillomavirus (HPV) vaccines”, Virus Research, Mar. 2017 (available online Nov. 2016), vol. 231, pp. 166-175 <DOI:10.1016/j.virusres.2016.11.020>. [cited by applicant]
Schmidt, N. et al., “Influenza virus a M2 protein generates negative Gaussian membrane curvature necessary for budding and scission”, Journal of the American Chemical Society, Sep. 2013, vol. 135, No. 37, pp. 13710-1371… [cited by applicant]
Schnell, J. et al., “Structure and mechanism of the M2 proton channel of influenza A virus”, Nature, Jan. 2008, vol. 451, No. 7178, pp. 591-595 <DOI:10.1038/nature06531>. [cited by applicant]
Schodel, F. et al., “The Position of Heterologous Epitopes Inserted in Hepatitis B Virus Core Particles Determines Their Immunogenicity”, Journal of Virology, Jan. 1992, vol. 66, No. 1, pp. 106-114. [cited by applicant]
Scorza, F. et al., “Universal influenza vaccines: Shifting to better vaccines”, Vaccine, Jun. 2016 (available online Mar. 2016), vol. 34, No. 26, pp. 2926-2933 <DOI:10.1016/j.vaccine.2016.03.085>. [cited by applicant]
Sharma, D. et al., “Interleukin-4 Mediates Down Regulation of Antiviral Cytokine Expression and Cytotoxic T- Lymphocyte Responses and Exacerbates Vaccinia Virus Infection In Vivo”, Journal of Virology, Oct. 1996, vol. 7… [cited by applicant]
Shields, R. et al., “Lack of Fucose on Human IgG1 N-Linked Oligosaccharide Improves Binding to Human FcγRIII and Antibody-dependent Cellular Toxicity”, The Journal of Biological Chemistry, Jul. 2002 (available online Ma… [cited by applicant]
Simón, D. et al., “Host influence in the genomic composition of flaviviruses: A multivariate approach”, Biochemical and Biophysical Research Communications, Oct. 2017 (available online Jun. 2017), vol. 492, No. 4, pp. 5… [cited by applicant]
Skehel, J. et al., “Receptor Binding and Membrane Fusion in Virus Entry: The Influenza Hemagglutinin”, Annual Review of Biochemistry, Jul. 2000, vol. 69, No. 1, pp. 531-569 <DOI:10.1146/annurev.biochem.69.1.531>. [cited by applicant]
Skowronski, D. et al., “Early season co-circulation of influenza A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness, Canada, Jan. 2018”, Eurosurveillance, Feb. 2018, vol. 23, No. 5, 7 pp. <DOI:1… [cited by applicant]
Smith, D. et al., “Detection of influenza C virus but not influenza D virus in Scottish respiratory samples”, Journal of Clinical Virology, Jan. 2016 (available online Nov. 2015), vol. 74, pp. 50-53 <DOI:10.1016/j.jcv.2… [cited by applicant]
Aguilar, J. et al., “Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen”, Immunology… [cited by applicant]
Alam, A. et al., “Technoeconomic Modeling of Plant-Based Griththsin Manufacturing”, Frontiers in Bioengineering and Biotechnology, Jul. 2018, vol. 6, No. 102, 13 pages <DOI:10.3389/fbioe.2018.00102>. [cited by applicant]
Ali, S. et al., “Mitigation of Influenza B Epidemic with School Closures, Hong Kong, 2018”, Emerging Infectious Diseases, Nov. 2018, vol. 24, No. 11, pp. 2071-2073 <DOI:10.3201/eid2411.180612>. [cited by applicant]
Alphs, H. et al., “Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2”, Proceedings of the National Academy of Science… [cited by applicant]
Atsmon, J. et al., “Safety and Immunogenicity of Multimeric-001—a Novel Universal Influenza Vaccine”, Journal of Clinical Immunology, Jun. 2012 (available online Feb. 2012), vol. 32, No. 3, pp. 595-603 <DOI:10.1007/s108… [cited by applicant]
Avalos, A. et al., “Early BCR events and antigen capture, processing, and loading on MHC class II on B cells”, Frontiers in Immunology, Mar. 2014, vol. 5, No. 92, 5 pages <DOI:10.3389/fimmu.2014.00092>. [cited by applicant]
Bajtay, Z. et al., “Expression and role of Fc- and complement-receptors on human dendritic cells”, Immunology Letters, Apr. 2006 (available online Dec. 2005), vol. 104, No. 1-2, pp. 46-52 <DOI:10.1016/j.imlet.2005.11.02… [cited by applicant]
Barzon, L. et al., “Current views on Zika virus vaccine development”, Expert Opinion on Biological Therapy, Jun. 2017, vol. 17, No. 10, pp. 1185-1192 <DOI:10.1080/14712598.2017.1346081>. [cited by applicant]
Belmusto-Worn, V. et al., “Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants an… [cited by applicant]
Bianchi, E. et al., “Universal Influenza B Vaccine Based on the Maturational Cleavage Site of the Hemagglutinin Precursor”, Journal of Virology, Jun. 2005, vol. 79, No. 12, pp. 7380-7388 <DOI: 10.1128/JVI.79.12.7380-738… [cited by applicant]
Black, R. et al., “Antibody response to the M2 protein of influenza A virus expressed in insect cells”, Journal of General Virology, Jan. 1993, vol. 74, No. 1, pp. 143-146 <DOI:10.1099/0022-1317-74-1-143>. [cited by applicant]
Blokhina, E. et al., “A molecular assembly system for presentation of antigens on the surface of HBc virus-like particles”, Virology, Jan. 2013 (available online Oct. 2012), vol. 435, No. 2, pp. 293-300 <DOI:10.1016/j.v… [cited by applicant]
Boigard, H. et al., “Zika virus-like particle (VLP) based vaccine”, PLoS Neglected Tropical Diseases, May 2017, vol. 11, No. 5, article e0005608, 20 pages <DOI:10.1371/journal.pntd.0005608>. [cited by applicant]
Breese, J. et al., “Estimated influenza illnesses and hospitalizations averted by influenza vaccination-United States, 2012-13 influenza season”, Morbidity and Mortality Weekly Report, Dec. 2013, vol. 62, No. 49, pp. 99… [cited by applicant]
Breitburd, F. et al., “Immunization with Viruslike Particles from Cottontail Rabbit Papillomavirus (CRPV) Can Protect against Experimental CRPV Infection”, Journal of Virology, Jun. 1995, vol. 69, No. 6, pp. 3959-3963. [cited by applicant]
Bresee, J. et al., “Progress and Remaining Gaps in Estimating the Global Disease Burden of Influenza”, Emerging Infectious Diseases, Jul. 2018, vol. 24, No. 7, pp. 1173-1177 <DOI:10.3201/eid2407.171270>. [cited by applicant]
Brown, A. et al., “Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted”, Vaccine, Aug. 1991 (available online Dec. 2002), vol. 9, No. 8, pp. 59… [cited by applicant]
Brown, D. et al., “The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Generally HPV-Naive Wome… [cited by applicant]
Buck, C. et al., “Arrangement of L2 within the Papillomavirus Capsid”, Journal of Virology, Jun. 2008 (available online Mar. 2008), vol. 82, No. 11, pp. 5190-5197 <DOI:10.1128/JVI.02726-07>. [cited by applicant]
Buck, C. et al., “Generation of HPV Pseudovirions Using Transfection and Their Use in Neutralization Assays”, Human Papillomaviruses, 2005, vol. 119, pp. 445-462 <DOI:10.1385/1-59259-982-6:445>. [cited by applicant]
Buck, C. et al., “Production of Papillomavirus-Based Gene Transfer Vectors”, Current Protocols in Cell Biology, Dec. 2007, vol. 37, No. 1, pp. 26.1.1-26.1.19 <DOI:10.1002/0471143030.cb2601s37>. [cited by applicant]
Burns, A. et al., “Evaluating the Economic Consequences of Avian Influenza”, The World Bank: Documents and Reports, Jun. 2006, vol. 1, No. 47417, 6 pages. [cited by applicant]
Caini, S. et al., “Characteristics of seasonal influenza A and B in Latin America: Influenza surveillance data from ten countries”, PLoS One, Mar. 2017, vol. 12, No. 3, article e0174592, 12 pages <DOI:10.1371/journal.po… [cited by applicant]
Castilho, A. et al., “Glyco-engineering in plants to produce human-like N-glycan structures”, Biotechnology Journal, Sep. 2012 (available online Aug. 2012), vol. 7, No. 9, pp. 1088-1098 <DOI:10.1002/biot.201200032>. [cited by applicant]
Centers for Disease Control and Prevention (CDC)., “Summary of the 2017-2018 Influenza Season” [online], Influenze (Flu), 2017 [retrieved Jul. 23, 2019 from archive.org, as it appeared on Nov. 2, 2018], retrieved from t… [cited by applicant]
Cerovska, N. et al., &#8220; Transient expression of Human papillomavirus type 16 L2 epitope fused to N- and C-terminus of coat protein of Potato virus X in plants, Journal of Biosciences, Mar. 2012 (available online Ja… [cited by applicant]
Chackerian, B., “Virus-like particles: flexible platforms for vaccine development”, Expert Review of Vaccines, 2007 (available online Jan. 2014), vol. 6, No. 3, pp. 381-390 <DOI:10.1586/14760584.6.3.381>. [cited by applicant]
Chargelegue, D. et al., “Highly Immunogenic and Protective Recombinant Vaccine Candidate Expressed in Transgenic Plants”, Infection and Immunity, Sep. 2005, vol. 73, No. 9, pp. 5915-5922 <DOI:10.1128/IAI.73.9.5915-5922.… [cited by applicant]
Chen, Q. et al., “Geminiviral vectors based on bean yellow dwarf virus for production of vaccine antigens and monoclonal antibodies in plants”, Human Vaccines, Mar. 2011, vol. 7, No. 3, pp. 331-338 <DOI:10.4161/hv.7.3.1… [cited by applicant]
Clarkson, S. et al., “Blockade of clearance of immune complexes by an anti-F(cγ) receptor monoclonal antibody”, Journal of Experimental Medicine, Aug. 1986, vol. 164, No. 2, pp. 474-489 <DOI:10.1084/jem.164.2.474>. [cited by applicant]
Cohen, J., “High Hopes and Dilemmas for a Cervical Cancer Vaccine”, Science, Apr. 2005, vol. 308, No. 5722, pp. 618-621 <DOI:10.1126/science.308.5722.618>. [cited by applicant]
Cooper, A. et al., “Cytokine Induction by the Hepatitis B Virus Capsid in Macrophages Is Facilitated by Membrane Heparan Sulfate and Involves TLR2”, The Journal of Immunology, Sep. 2005, vol. 175, No. 5, pp. 3165-3176 <… [cited by applicant]
Cornacoff, J. et al., “Primate erythrocyte-immune complex-clearing mechanism”, Journal of Clinical Investigation, Feb. 1983, vol. 7, No. 2, pp. 236-247 <DOI:10.1172/JCI110764>. [cited by applicant]
Coutelier, J. et al., “Virally induced modulation of murine IgG antibody subclasses”, Journal of Experimental Medicine, Dec. 1988, vol. 168, No. 6, pp. 2373-2378 <DOI:10.1084/jem.168.6.2373>. [cited by applicant]
Crow, J., “HPV: The global burden”, Nature, Aug. 2012, vol. 488, pp. S2-S3 <DOI:10.1038/488S2a>. [cited by applicant]
Dai, L. et al., “Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody”, Cell Host & Microbe, May 2016, vol. 19, No. 5, pp. 696-704 <DOI:10.1016/j.chom.2016.04.013>. [cited by applicant]
Davies, J. et al., “Geminivirus genes and vectors”, Trends in Genetics, 1989 (available online Jan. 2003), vol. 5, pp. 77-81 <DOI:10.1016/0168-9525(89)90030-9>. [cited by applicant]
Davies, K. et al., “Splenic uptake of immune complexes in man is complement-dependent”, Journal of Immunology, Oct. 1993, vol. 151, No. 7, pp. 3866-3873. [cited by applicant]
De Filette, M. et al., “An Influenza A Vaccine Based on Tetrameric Ectodomain of Matrix Protein 2”, Journal of Biological Chemistry, Apr. 2008, vol. 283, No. 17, pp. 11383-11387 <DOI:10.1074/jbc.M800650200>. [cited by applicant]
De Jong, J. et al., “Murine Fc receptors for IgG are redundant in facilitating presentation of immune complex derived antigen to CD8+ T cells in vivo”, Molecular Immunology, May 2006 (available online Feb. 2006), vol. 4… [cited by applicant]
Deng, L. et al., “M2e-Based Universal Influenza A Vaccines”, Vaccines, Mar. 2015 (available online Feb. 2015), vol. 3, No. 1, pp. 105-136 <DOI:10.3390/vaccines3010105>. [cited by applicant]
Diamos et al., “5' and 3' Untranslated Regions Strongly Enhance Performance of Geminiviral Replicons in Nicotiana benthamiana Leaves”, Front Plant Sci, (Feb. 24, 2016), vol. 7, No. 200, pp. 1-15. [cited by applicant]
Diamos et al., “Chimeric 3' flanking regions strongly enhance gene expression in plants”, Plant Biotechnol J, (May 21, 2018), vol. 16, pp. 1971-1982. [cited by applicant]
Diamos, A. et al., “Codelivery of improved immune complex and virus-like particle vaccines containing Zika virus envelope domain III synergistically enhances immunogenicity”, Vaccine, Apr. 2020 (available online Mar. 20… [cited by applicant]
Diamos, A. et al., “High Level Production of Monoclonal Antibodies Using an Optimized Plant System”, Frontiers in Bioengineering and Biotechnology, Jan. 2020, vol. 7, article 472 <DOI:10.3389/fbioe.2019.00472>. [cited by applicant]
Diamos, A. et al., “High-level expression and enrichment of norovirus virus-like particles in plants using modified geminiviral vectors”, Protein Expression and Purification, Nov. 2018 (Jun. 2018), vol. 151, pp. 86-92 >… [cited by applicant]
Diamos, A. et al., “Modifying the Replication of Geminiviral Vectors Reduces Cell Death and Enhances Expression of Biopharmaceutical Proteins in Nicotiana benthamiana Leaves”, Frontiers in Plant Science, Jan. 2019, vol.… [cited by applicant]
Diamos, A. et al., “Vaccine synergy with virus-like particle and immune complex platforms for delivery of human papillomavirus L2 antigen”, Vaccine, Jan. 2019 (available online Nov. 2018), vol. 37, No. 1, pp. 137-144 <D… [cited by applicant]
Division of STD Prevention., “Prevention of Genital HPV Infection and Sequelae: Report of an External Consultants' Meeting”, Department of Health and Human Services, Atlanta: Centers of Disease Control and Prevention, D… [cited by applicant]
Doorbar, J. et al., “Human papillomavirus molecular biology and disease association”, Reviews in Medical Virology, Mar. 2015, vol. 25, No. S1, pp. 2-23 <D01:10.1002/rmv.1822>. [cited by applicant]
Spreitzer, R. et al., “Rubisco: Structure, Regulatory Interactions, and Possibilities for a Better Enzyme”, Annual Review of Plant Biology, Jun. 2002, vol. 53, pp. 449-475 <DOI:10.1146/annurev.arplant.53.100301.135233>. [cited by applicant]
Stahl, S. et al., “Immunogenicity of peptide fusions to hepatitis B virus core antigen”, Proceedings of the National Academy of Sciences of the United States of America, Aug. 1989, vol. 86, No. 16, pp. 6283-6287 <DOI:10… [cited by applicant]
Stanley, J., “Geminiviruses: plant viral vectors”, Current Opinion in Genetics & Development, Feb. 1993 (available online Aug. 2005), vol. 3, No. 1, pp. 91-96 <DOI:10.1016/S0959-437X(05)80347-8>. [cited by applicant]
Stanley, M. et al., “Immunobiology of Human Papillomavirus Infection and Vaccination—Implications for Second Generation Vaccines”, Vaccine, Aug. 2008 (available online Sep. 2008), vol. 26, Supplement 10, pp. K62-K67 <DO… [cited by applicant]
Stemmer, W. et al., “Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides”, Gene, Oct. 1995 (available online Dec. 1999), vol. 164, No. 1, pp. 49-53 <DOI:10.1016/0378-1119(95… [cited by applicant]
Stepanova, L. et al., “Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes”, Journal of Biomedical Science, Apr. 2018,… [cited by applicant]
Stettler, K. et al., “Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection”, Science, Aug. 2016, vol. 353, No. 6301, pp. 823-826 <DOI:10.1126/science.aaf8505>. [cited by applicant]
Strasser, R. et al., “Controlled glycosylation of plant-produced recombinant proteins”, Current Opinion in Biotechnology, Dec. 2014 (available online Jul. 2014), vol. 30, pp. 95-100 <DOI:10.1016/j.copbio.2014.06.008>. [cited by applicant]
Strasser, R. et al., “Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure”, Plant Biotechnology Journal, May 2008 (available … [cited by applicant]
Streatfield, S. et al., “Plant-based vaccines: unique advantages”, Vaccine, Mar. 2001, vol. 19, No. 17-19, pp. 2742-2748 <DOI:10.1016/S0264-410X(00)00512-0>. [cited by applicant]
Su, S. et al., “Novel Influenza D virus: Epidemiology, pathology, evolution and biological characteristics”, Virulence, Aug. 2017, vol. 8, No. 8, pp. 1580-1591 <DOI:10.1080/21505594.2017.1365216>. [cited by applicant]
Suarez, D., “Influenza A virus”, Animal Influenza, Nov. 2016, 2nd edition, 29 pages <DOI:10.1002/9781118924341.ch1>. [cited by applicant]
Sullivan, S. et al., “Low interim influenza vaccine effectiveness, Australia, May 1 to Sep. 24, 2017”, Eurosurveillance, Oct. 2017, vol. 22, No. 43, 7 pages <DOI:10/807/1560-7917.ES.2017.22.43.17-00707>. [cited by applicant]
Takai, T. et al., “FcR γ chain deletion results in pleiotrophic effector cell defects”, Cell, Feb. 1994 (available online Apr. 2004), vol. 76, No. 3, pp. 519-529 <DOI:10.1016/0092-8674(94)90115-5>. [cited by applicant]
Taylor, A. et al., “Fc receptors in antibody-dependent enhancement of viral infections”, Immunological Reviews, Nov. 2015 (available online Oct. 2015), vol. 268, No. 1, pp. 340-364 <DOI:10.1111/imr.12367>. [cited by applicant]
Thielens, N. et al., “C1q: A fresh look upon an old molecule”, Molecular Immunology, Sep. 2017 (Jun. 2017), vol. 89, pp. 73-83 <DOI:10.1016/j.molimm.2017.05.025>. [cited by applicant]
Thompson, W. et al., “Influenza-Associated Hospitalizations in the United States”, JAMA, Sep. 2004, vol. 292, No. 11, pp. 1333-1340 <DOI:10.1001/jama.292.11.1333>. [cited by applicant]
Tiwari, S. et al., “Plants as bioreactors for the production of vaccine antigens”, Biotechnology Advances, Jul.-Aug. 2009 (available online Apr. 2009), vol. 27, No. 4, pp. 449-467 <DOI:10.1016/j.biotechadv.2009.03.006>. [cited by applicant]
Turley, C. et al., “Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults”, Vaccine, Jul. 2011 (available online May 2011), vol. 29, No. 32, pp. 5145-5152 <DOI:10.1016… [cited by applicant]
Tusé, D., Tu, T., and McDonald, K. A. (2014). “Manufacturing Economics of Plant-Made Biologics: Case Studies in Therapeutic and Industrial Enzymes.” Biomed Res. Int. 2014, 1-16. doi: 10.1155/2014/256135. [cited by applicant]
Van Den Hoecke, S. et al., “Hierarchical and Redundant Roles of Activating FcRs in Protection against Influenza Disease by M2e-Specific IgG1 and IgG2a Antibodies”, Journal of Virology, Apr. 2017, vol. 91, No. 7, article… [cited by applicant]
Vesikari, T. et al., “A Randomized, Double-Blind, Phase III Study of the Immunogenicity and Safety of a 9-Valent Human Papillomavirus L1 Virus-Like Particle Vaccine (V503) Versus Gardasil® in 9-15-Year-Old Girls”, The P… [cited by applicant]
Vignesh, P. et al., “Complement in autoimmune diseases”, Clinica Chimica Acta, Feb. 2017 (available online Dec. 2016), vol. 465, pp. 123-130 <DOI:10.1016/j.cca.2016.12.017>. [cited by applicant]
Villa, L. et al., “Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial… [cited by applicant]
Wang, J. et al., “L2, the minor capsid protein of papillomavirus”, Virology, Oct. 2013 (available online May 2013), vol. 445, No. 1-2, pp. 175-186 <DOI:10.1016/j.virol.2013.04.017>. [cited by applicant]
Wang, J. et al., “Roles of Fc Domain and Exudation in L2 Antibody-Mediated Protection against Human Papillomavirus”, Journal of Virology, Aug. 2018 (available online May 2018), vol. 92, No. 15, 17 pages <DOI:10.1128/JV1… [cited by applicant]
Webster, G. et al., “A polymeric immunoglobulin-antigen fusion protein strategy for enhancing vaccine immunogenicity”, Plant Biotechnology Journal, Dec. 2018 (available online Apr. 2018), vol. 16, No. 12, pp. 1983-1996 … [cited by applicant]
Webster, R. et al., “Molecular mechanisms of variation in influenza viruses”, Nature, Mar. 1982, vol. 296, pp. 115-121 <DOI:10.1038/296115a0>. [cited by applicant]
Wen, Y-M, et al., “Immunoregulatory functions of immune complexes in vaccine and therapy”, EMBO Molecular Medicine, Oct. 2016 (available online Aug. 2016), vol. 8, No. 10, pp. 1120-1133 <DOI:10.15252/emmm.201606593>. [cited by applicant]
Wheeler, C. et al., “The Impact of Quadrivalent Human Papillomavirus (HPV; Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine on Infection and Disease Due to Oncogenic Nonvaccine HPV Types in Sexually Active Women … [cited by applicant]
Whitacre, D. et al., “Use of hepadnavirus core proteins as vaccine platforms”, Expert Review of Vaccines, Jan. 2009 (available online Jan. 2014), vol. 8, No. 11, pp. 1565-1573 <DOI:10.1586/erv.09.121>. [cited by applicant]
Wilder-Smith, A. et al., “Zika vaccines and therapeutics: landscape analysis and challenges ahead”, BMC Medicine, Jun. 2018, vol. 16, No. 84, 15 pages <DOI:10.1186/s12916-018-1067-x>. [cited by applicant]
Wilson, J. et al., “Epitopes Involved in Antibody-Mediated Protection from Ebola Virus”, Science, Mar. 2000, vol. 287, No. 5458, pp. 1664-1666 <DOI:10.1126/science.287.5458.1664>. [cited by applicant]
World Health Organization., “Influenza (Seasonal) Fact Sheet” [online], WHO, 2018 [retrieved on Jul. 26, 2019 from archive.org, as it appeared on Mar. 24, 2019], retrieved from the internet: <URL:https://web.archive.org… [cited by applicant]
Yang, M. et al., “Immunization of Zika virus envelope protein domain III induces specific and neutralizing immune responses against Zika virus”, Vaccine, Jul. 2017 (available online Jun. 2017), vol. 35, No. 33, pp. 4287… [cited by applicant]
Yang, M. et al., “Plant-produced Zika virus envelope protein elicits neutralizing immune responses that correlate with protective immunity against Zika virus in mice”, Plant Biotechnology Journal, Feb. 2018 (available o… [cited by applicant]
Yang, M. et al., “Virus-like particles that display Zika virus envelope protein domain III induce potent neutralizing immune responses in mice”, Scientific Reports, Aug. 2017, vol. 7, No. 7679, 12 pages <DOI:10.1038/s41… [cited by applicant]
Yang, R. et al., “Cell Surface-Binding Motifs of L2 That Facilitate Papillomavirus Infection”, Journal of Virology, Mar. 2003, vol. 77, No. 6, pp. 3531-3541 <DOI:10.1128/JVI.77.6.3531-3541.2003>. [cited by applicant]
Zebedee, S. et al., “Influenza A Virus M2 Protein: Monoclonal Antibody Restriction of Virus Growth and Detection of M2 in Virions”, Journal of Virology, Aug. 1988, vol. 62, No. 8, pp. 2762-2772. [cited by applicant]
Zeitlin, L. et al., “Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant”, Proceedings of the National Academy of Sciences of the United States of America, Dec. 2011,… [cited by applicant]
Zhai, L. et al., “A novel candidate HPV vaccine: MS2 phage VLP displaying a tandem Hpv L2 peptide offers similar protection in mice to Gardasil-9”, Antiviral Research, Nov. 2017 (available online Sep. 2017), vol. 147, p… [cited by applicant]
Zhang, J. et al., “Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice”, Vaccine, Jan. 2016 (available online De… [cited by applicant]
Zhang, X. et al., “Structures and Functions of the Envelope Glycoprotein in Flavivirus Infections”, Viruses, Nov. 2017, vol. 9, No. 11, 14 pages <DOI:10.3390/v9110338>. [cited by applicant]
Zhao H. et al., “Structural Basis of Zika Virus-Specific Antibody Protection”, Cell, Aug. 2016 (available online Jul. 2016), vol. 166, No. 4, pp. 1016-1027 <DOI:10.1016/j.cell.2016.07.020>. [cited by applicant]
Zhou, C. et al., “Immunization with high epitope density of M2e derived from 2009 pandemic H1N1 elicits protective immunity in mice”, Vaccine, May 2012 (available online Mar. 2012), vol. 30, No. 23, pp. 3463-3469 <DOI:1… [cited by applicant]